Fritextsökning
Artiklar per år
Innehållstyper
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs are high, and demand is weak”, says the division manager at Rise to Life Science Sweden.
-
Norska bolag slås ihop – ”Dödsstöten”
De norska företagen Ultimovacs och Zelluna Immunotherapy planerar att gå samman. Samtidigt står det klart att Ultimovacs vd lämnar företaget och en norsk analytiker bedömer ihopslagningen som ”dödsstöten” för Ultimovacs cancervaccin.
-
Kritiserat bolag hotas av avnotering
Bio Vitos Pharma hotas av avnotering från Nasdaq efter anklagelser om bristande informationsgivning.
-
Börsnoterade Cyxone ansöker om konkurs
Cyxone, ett Malmöbaserat bioteknikföretag inom autoimmuna sjukdomar, meddelar att bolaget beslutat att ansöka om konkurs.
-
”Ett av våra mest efterfrågade möten” arrangeras för tionde gången
Snart är det dags för Life Science Swedens event Pharma Outsourcing. Träffa branschkollegor, lär dig nytt och gör viktiga affärer den 3 december i Life City i Hagastaden.
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
Uppsalabolag riskerar avnotering – anklagas för bristande informationsgivning
Quia Pharma riskerar avnotering sedan Nasdaq påpekat vad som bedöms vara brister i informationsgivningen.
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
Peptonic drar sig ur Israel – "Ökade svårigheter"
Peptonic Medical har beslutat att avveckla sitt israeliska dotterbolag på grund av ”lönsamhetsutmaningar” och ”ökade svårigheter att bedriva verksamhet” i landet.
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What we see is a significant unmet need, so we are expecting to have quite a good welcoming
-
From lab to patient – the art of developing new antibody therapies
For 25 years, Danish company Genmab has been developing antibodies and has managed to get several drugs all the way to the patient. Esther Breij has been along for much of the journey and has experienced setbacks, but also huge discoveries. “It’s amazing when you succeed,” she says.
-
Ny säljchef på GBA Key2Compliance
Konsultbolaget Key2compliance har rekryterat Anders Jeppson som ny Director of Sales och nu bytt namn till GBA Key2compliance som en följd av att GBA Group tidigare i år förvärvade företaget.
-
Sobi announces agreement with Enable Injections
Swedish biopharma Sobi has entered into an international development and distribution agreement with US drug delivery company Enable Injections.
-
Företagare föreslås ta över klubban i Lundabolaget CLS
Både ordföranden och en styrelseledamot meddelar att de lämnar det skånska företaget Clinical Laserthermia Systems. Till ny ordförande föreslås företagaren Peter Max.
-
Takeover bid is being completed – Japanese company acquires Calliditas
Japanese company Asahi Kasei completes the bid for Calliditas Therapeutics after reaching over 90 percent of the shareholding. Callidita's board has now decided to apply for delisting of the company´s share from Nasdaq Stockholm.
-
Danish biotech to buy struggling American oncology company
Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.
-
The investor: “The major common diseases are hot again”
She has previously been voted Investor of the Year and will now be moderating The Future of Swedish & Danish Life Science congress. We check the temperature of the industry with Nina Rawal from Trill Impact Advisory.
-
Thumbs down for lecanemab in the EU – “Very surprised”
The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), according to an announcement made by the Agency last week. Bioarctic’s CEO Gunilla Osswald describes the reactions after the announcement as a surprise and disappointment.
-
Redwood Pharma auktionerar ut tillgångar – förväntas vara klart i juli
Forskningsbolaget Redwood Pharma har bjudit in ett flertal oftalmologibolag i USA, Europa och Asien att delta i en auktionsprocess rörande bolagets tillgångar. Processen förväntas kunna avslutas under juli.
-
Innovative start-up helps doctors, scientists and industry balance coagulation risks
For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thrombosis is an ongoing challenge. In the late 1980s, scientists at Maastricht University in the Netherlands developed an innovative method, the thrombin generation assay (TGA), which provides a complete overview of a physiological process crucial for maintaining normal haemostasis.
-
Omvänt förvärv ska ta Flerie till börsen – ”Viktigt steg i bolagets plan”
Läkemedelsinvesteraren Flerie Invest tar en genväg till börsen genom ett omvänt förvärv av forskningsbolaget Index Pharmaceuticals.
-
Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed
Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.
-
Han tar över ordförandeklubban i Sweden Bio
Branschorganisationen Sweden Bio har utsett Anders Persson från Astra Zeneca till ny styrelseordförande.
-
Carl Borrebaeck – professor and serial entrepreneur with a taste for speed
Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.
BREAKING